P-wave Terminal Force in Patients With Atrial Fibrillation.
Ptf-AF
1 other identifier
observational
600
1 country
1
Brief Summary
It is suggested that P-wave terminal force (Ptf), a product of the amplitude (PAM) and the duration (PT) of the terminal phase of P-wave in lead V1, shows early delay in left atrial conduction, observed earlier that the dilatation of left atrium. The aim is to follow PT, PAM and Ptf changes during 5-year follow-up (5FU) and examine the relation of these changes to the number of AF episodes requiring hospitalisation (HOSP) for restoration of sinus rhythm (RSR).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 2, 2018
CompletedFirst Posted
Study publicly available on registry
February 12, 2018
CompletedStudy Start
First participant enrolled
March 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 7, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 7, 2020
CompletedJanuary 22, 2020
January 1, 2020
2 years
February 2, 2018
January 20, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes of P-wave time (PT), P-wave amplitude (PAM) and Ptf (P wave terminal force terminal V1-lead ) in 5-year follow-up (5FU).
All measurements based on ECG recording during sinus rhythm only. * "P-wave time (PT)" defined as time (measured in milliseconds, \[ms\]) of negative deflection of P wave in V1 lead of the standard 12-lead ECG; * "P-wave amplitude (PAM)" defined as maximum amplitude (measured in millivolts, \[mV\]) of negative deflection of P wave in V1 lead of the standard 12-lead ECG; * "P-wave terminal force (Ptf)" is a product of the amplitude and the duration of the terminal phase of P-wave in lead V1; Ptf = PT x PAM \[ms x mV\]; * PT and PAM measured at index is defined as PT0 and PAM0, respectively * Calculated Ptf as a product of PT0 and PAM0 is defined as Ptf0; * PT and PAM measured at 5FU is defined as PT5 and PAM5, respectively; * Calculated Ptf as a product of PT5 and PAM5 is defined as Ptf5; * The change between PT0 and PT5 (PTC = PT5 - PT0) , PAM0 and PAM5 (PAMC = PAM5 - PAM0), Ptf0 and Ptf5 (PtfC = Ptf5 - Ptf0) will be calculated for each patient;
5 years
Secondary Outcomes (3)
Correlation between index PT0, PAM0, Ptf0 and number of hospitalizations (HOSP) in 5-year follow-up
5 years
Correlation between number of hospitalizations (HOSP) in 5- year follow-up and final PT5, PAM5, Ptf5 at the end of 5-year follow-up period.
5 years
Correlation between changes of PT, PAM, Ptf (PTC, PAMC, PtfC) and number of hospitalizations (HOSP) in 5-year follow-up.
5 years
Interventions
Direct current (DC) cardioversion for sinus rhythm restoration
Eligibility Criteria
Patients with atrial fibrillation admitted between 1.1.2001 and 30.12.2012 for elective and emergency hospitalization aimed for restoration of sinus rhythms with DC cardioversion.
You may qualify if:
- documented atrial fibrillation at admission
- successful restoration of sinus rhythms documented in 12-leads ECG,
- follow-up =\> 5 years
You may not qualify if:
- arrhythmia other than atrial fibrillation at admission,
- unsuccessful restoration of sinus rhythms,
- successful restoration of sinus rhythms but missing 12-leads ECG recording,
- previous ablation/operation within left atrium,
- follow-up \< 5 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Medical University of Lublin
Lublin, 20-091, Poland
Related Publications (4)
Wojcik M, Kuniss M, Berkowitsch A, Neumann T. P-wave terminal force and atrial fibrillation: a lesson learned from old masters. Rev Esp Cardiol (Engl Ed). 2012 Jun;65(6):584-5; author reply 585. doi: 10.1016/j.recesp.2012.01.015. Epub 2012 Mar 31. No abstract available.
PMID: 22465604BACKGROUNDJanin S, Wojcik M, Kuniss M, Berkowitsch A, Erkapic D, Zaltsberg S, Ecarnot F, Hamm CW, Pitschner HF, Neumann T. Pulmonary vein antrum isolation and terminal part of the P wave. Pacing Clin Electrophysiol. 2010 Jul;33(7):784-9. doi: 10.1111/j.1540-8159.2010.02754.x. Epub 2010 Mar 29.
PMID: 20374516BACKGROUNDIshida K, Hayashi H, Miyamoto A, Sugimoto Y, Ito M, Murakami Y, Horie M. P wave and the development of atrial fibrillation. Heart Rhythm. 2010 Mar;7(3):289-94. doi: 10.1016/j.hrthm.2009.11.012. Epub 2009 Nov 12.
PMID: 20133209BACKGROUNDMartin Garcia A, Jimenez-Candil J, Hernandez J, Martin Garcia A, Martin Herrero F, Martin Luengo C. P wave morphology and recurrence after cardioversion of lone atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2012 Mar;65(3):289-90. doi: 10.1016/j.recesp.2011.04.023. Epub 2011 Jul 30. No abstract available. English, Spanish.
PMID: 21803476BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Maciej Wójcik, MD, PhD
Medical University of Lublin, Poland
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
February 2, 2018
First Posted
February 12, 2018
Study Start
March 1, 2018
Primary Completion
March 7, 2020
Study Completion
December 7, 2020
Last Updated
January 22, 2020
Record last verified: 2020-01